Mid-Stage Win Gives 89Bio a Boost in NASH Race
Data from the Phase IIb ENLIVEN trial showed 89bio’s pegozafermin met its primary histology endpoint in NASH patients, giving the company an edge in the competitive space.
The Home of the Life Sciences Industry
Pfizer-Backed Flare Seeks Transcription Factor Therapies with $123M Series B
Flare Therapeutics closed Wednesday an oversubscribed Series B funding round, counting $123 million in earnings, which it will use to advance its lead precision oncology asset FX-909 in urothelial cancer.
More Top Stories
- The Rise, Fall and Future of Novavax
- FDA's Marks Supports Accelerated Approval for Gene Therapies
- Mereo Forges Ahead with PRO Trial Design for Lung Disease Program
- With CTLA-4 Antibody Deal, BioNTech Comes Face-to-Face with BMS' Ye...
- FDA Releases Briefing Docs for Upcoming Biogen/Ionis Tofersen Adcomm
